10 results on '"Gardin, Claude"'
Search Results
2. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.
- Author
-
Grignano, Eric, Mekinian, Arsene, Braun, Thorsten, Liozon, Eric, Hamidou, Mohamed, Decaux, Olivier, Puéchal, Xavier, Kahn, Jean Emmanuel, Schoindre, Yoland, Rossignol, Julien, Lortholary, Olivier, Lioger, Bertrand, Hermine, Olivier, Park, Sophie, Ades, Lionel, Montestruc, François, Ricard, Laure, Gardin, Claude, Fenaux, Pierre, and Fain, Olivier
- Subjects
- *
AUTOIMMUNE diseases , *RETROSPECTIVE studies , *INFLAMMATION treatment , *CHRONIC myeloid leukemia , *STEROID drugs , *DIAGNOSIS , *THERAPEUTICS ,MEDICAL literature reviews - Abstract
We wanted to describe the characteristics, treatment and outcome of autoimmune and inflammatory diseases (SAIDs) associated with chronic myelomonocytic leukemia (CMML), and conducted a French multicenter retrospective study and a literature review. We included 26 cases of CMML (median age 75 years, 54% female), 80% with CMML-1. CPSS score was low (0 or 1) in 75% of cases. SAIDS was systemic vasculitis in 54%. Diagnosis of the 2 diseases was concomitant in 31% cases, and CMML was diagnosed before SAIDs in 12 cases (46%). First line treatment for SAIDs consisted mostly of steroid, with 85% of response. Second-line treatment was needed in 40% cases. Six patients received hypomethylating agents, with 66% response on SAIDs. A literature review found 49 cases of CMML-associated SAIDs, in whom SAIDs was systemic vasculitis in 29% cases. Hence, vasculitis is the most frequent SAIDs associated with CMML. After initial response to steroids, recurrence and steroid-dependence were frequent. Hypomethylating agents may be interesting in this context. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
- Author
-
Fraison, Jean-Baptiste, Mekinian, Arsène, Grignano, Eric, Kahn, Jean-Emmanuel, Arlet, Jean-Benoit, Decaux, Olivier, Denis, Guillaume, Buchdahl, Anne-Laure, Omouri, Mohamed, Maigne, Gwenola, Aouba, Achille, Leon, Nathalie, Berthier, Sabine, Liozon, Eric, Park, Sophie, Gardin, Claude, Lortholary, Olivier, Rossignol, Julien, Fenaux, Pierre, and Fain, Olivier
- Subjects
- *
AZACITIDINE , *AUTOIMMUNE disease treatment , *DRUG efficacy , *MYELODYSPLASTIC syndromes , *CHRONIC leukemia , *IMMUNOSUPPRESSIVE agents - Abstract
This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
- Author
-
Harel, Stéphanie, Cherait, Amina, Berthon, Céline, Willekens, Christophe, Park, Sophie, Rigal, Marthe, Brechignac, Sabine, Thépot, Sylvain, Quesnel, Bruno, Gardin, Claude, Adès, Lionel, Fenaux, Pierre, and Braun, Thorsten
- Subjects
- *
MYELODYSPLASTIC syndromes , *HEALTH outcome assessment , *DECITABINE , *AZACITIDINE , *HEMATOPOIETIC stem cell transplantation , *PATIENTS , *DISEASE risk factors , *THERAPEUTICS - Abstract
Outcome of patients with high risk MDS and CMML who failed treatment with azacitidine remains poor with a median survival of 6 months, without established therapy available except allogeneic hematopoietic stem cell transplantation. The objective of our study was to evaluate efficacy of decitabine after azacitidine failure in a relatively large patient cohort based on conflicting results with 0–28% response rates (RR) in this setting in small patient series. Thirty-six consecutive high risk MDS and CMML patients who received decitabine after azacitidine failure were retrospectively reviewed. Response was based on IWG 2006 criteria for MDS and CMML with WBC <13 G/l and also included for proliferative CMML the evolution of WBC, splenomegaly (SMG) and extramedullary disease (EMD). Patients received a median number of 3 (range 1–27) cycles of decitabine and 12 patients received at least 6 cycles. Seven (19.4%) patients were responders including 3 marrow CR (mCR), 2 stable disease (SD) with HI-E, 1 SD with HI-N and HI-P and 1 SD with HI-N. In a CMML patient with SD, specific skin lesions resolved with decitabine. Responses were generally short lived (2–5 months) except 1 responder currently ongoing with +11 months follow up. Two non-responders had prolonged SD (without HI) of 21 and 27 months duration respectively. Median OS from onset of decitabine was 7.3 months, without significant difference between responders and non-responders. Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS. Thus, use of decitabine in such patients who failed or progressed after azacitidine cannot be recommended, underscoring the need for novel strategies in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
- Author
-
Thomas, Xavier, Raffoux, Emmanuel, Renneville, Aline, Pautas, Cécile, de Botton, Stéphane, de Revel, Thierry, Reman, Oumedaly, Terré, Christine, Gardin, Claude, Chelghoum, Youcef, Boissel, Nicolas, Quesnel, Bruno, Cordonnier, Catherine, Bourhis, Jean-Henri, Elhamri, Mohamed, Fenaux, Pierre, Preudhomme, Claude, Socié, Gérard, Michallet, Mauricette, and Castaigne, Sylvie
- Subjects
- *
ACUTE myeloid leukemia treatment , *HEALTH outcome assessment , *STEM cell transplantation , *CLINICAL trials , *MEDICAL statistics , *ADOLESCENT medicine , *CANCER relapse - Abstract
Abstract: Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
6. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
- Author
-
Abdelhamid, Emna, Preudhomme, Claude, Helevaut, Nathalie, Nibourel, Olivier, Gardin, Claude, Rousselot, Philippe, Castaigne, Sylvie, Gruson, Bérengère, Berthon, Céline, Soua, Zohra, and Renneville, Aline
- Subjects
- *
MYELOID leukemia , *BIOMARKERS , *POLYMERASE chain reaction , *GENETIC mutation , *GENE expression , *POLYMERIZATION - Abstract
Abstract: FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
7. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action
- Author
-
Lainey, Elodie, Thépot, Sylvain, Bouteloup, Cyrielle, Sébert, Marie, Adès, Lionel, Tailler, Maximilien, Gardin, Claude, de Botton, Stéphane, Baruchel, André, Fenaux, Pierre, Kroemer, Guido, and Boehrer, Simone
- Subjects
- *
PROTEIN-tyrosine kinases , *ENZYME inhibitors , *ACUTE myeloid leukemia treatment , *DRUG development , *ENZYME kinetics , *CANCER cells , *EPIDERMAL growth factor , *APOPTOSIS - Abstract
Abstract: Initially, tyrosine kinase inhibitors (TKIs) were developed as targeted therapies that would solely interfere with aberrant tyrosine kinase activation in malignant cells. Nevertheless, preclinical and clinical studies demonstrated that TKI also exhibit “off-target” effects, that is effects not mediated by the assumed mechanisms of action. We and others showed that the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib exert potent antineoplastic effects on EGFR-negative myeloblasts from patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Here, we undertook a side-by-side comparison of the anti-leukemic efficacy of four different TKI in MDS and AML. Besides the EGFR inhibitor erlotinib, which served as a point of reference, we employed the dual EGFR/HER2 TKI lapatinib, as well as the multikinase inhibitors dasatinib and sorafenib. All four drugs had anti-leukemic effects on cell line models of MDS/AML in vitro as well as on malignant blasts from MDS/AML patients ex vivo. We explored the biological phenomena underlying this anti-leukemic efficacy. Since it is established that a therapeutic benefit in MDS/AML can be conveyed by induction of cell cycle arrest, apoptosis and/or differentiation, we deciphered the individual contribution of these three phenomena to the anti-leukemic action of each of the four TKI. The concomitant assessment of the panel of TKI enables us thus to define (and quantify) their differential capacity to impact on the three biological phenomena, and provide further evidence that these mechanisms are not solely explained by on-target effects. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
8. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison
- Author
-
Boehrer, Simone, Adès, Lionel, Galluzzi, Lorenzo, Tajeddine, Nicolas, Tailler, Maximilien, Gardin, Claude, de Botton, Stéphane, Fenaux, Pierre, and Kroemer, Guido
- Subjects
- *
CHEMICAL inhibitors , *EPIDERMAL growth factor , *MYELODYSPLASTIC syndromes treatment , *MYELOID leukemia , *LEUKEMIA treatment , *APOPTOSIS , *PROTEIN-tyrosine kinases , *CELL differentiation , *THERAPEUTICS - Abstract
Abstract: Erlotinib and gefitinib, two inhibitors of the epidermal growth factor receptor (EGFR), can stimulate apoptosis and differentiation of myeloid cell lines that lack EGFR, unveiling a novel, therapeutically exploitable off-target effect of tyrosine kinase inhibitors. Here, we performed a side-by-side comparison of erlotinib and gefitinib effects on a broad spectrum of malignant myeloid cell lines, as well as on primary myeloblasts freshly purified from the bone marrow of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Both erlotinib and gefitinib induce apoptosis of a cell line (KG-1) that represents AML, and differentiation in another cell line (P39) derived from a patient with high-risk MDS. In this setting, erlotinib was more efficient than gefitinib. Erlotinib and gefitinib were equipotent in inducing apoptosis of primary CD34+ myeloblasts from MDS and AML patients, yet had no toxic effect on CD34+ progenitor cells from healthy donors. Although the response of individual MDS and AML patients in vitro was highly heterogeneous, the pro-apoptotic effects of erlotinib and gefitinib correlated significantly. These results suggest that erlotinib and gefitinib share a mechanistically related off-target effect that may be taken advantage of for the therapy of MDS and AML. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
- Author
-
Djamai, Hanane, Berrou, Jeannig, Dupont, Mélanie, Kaci, Anna, Ehlert, Jan Erik, Weber, Holger, Baruchel, André, Paublant, Fabrice, Prudent, Renaud, Gardin, Claude, Dombret, Hervé, and Braun, Thorsten
- Subjects
- *
ACUTE myeloid leukemia , *SMALL molecules , *DECITABINE , *AZACITIDINE , *CELLS , *CELL growth - Abstract
• LIM kinase 1 and 2 are expressed in FLT3-ITD mutated AML cell lines. • The LIMK1/2 inhibitor CEL_Amide has antiproliferative effects in those cells. • CEL_Amide synergizes with FLT3-ITD inhibitors in vitro and in vivo. • Dephosphorylation of cofilin constitutes a potential biomarker for LIMK1/2 action. Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactivate cofilin by phosphorylation which affects cytoskeleton dynamics, cell growth and apoptosis. LIMK inhibition leads to cofilin activation via dephosphorylation and activated cofilin localizes to mitochondria inducing apoptosis. Thus, we investigated the therapeutic potential of the LIMK1/2 inhibitor CEL_Amide (LIMKi) in FLT3-ITD+ AML. Expression of LIMK1/2 in FLT3-ITD+ cell lines MOLM-13 and MV-4-11 cells could be detected by RT-qPCR and at the protein level. IC50 after LIMKi monotherapy was 440 nM in MOLM-13 cells and 420 nM in MV4-11 cells. Treatment with LIMKi decreased LIMK1 protein levels and repression of inactivating phosphorylation of cofilin in FLT3-ITD+ cells. Combination experiments with LIMKi and FLT3 inhibitors including midostaurin, crenolanib and gilteritinib were synergistic for treatment of MOLM-13 cells while combinations with quizartinib were additive. Combinations of LIMKi and the hypomethylating agent azacitidine or the ROCK inhibitor fasudil were additive. In NOD-SCID mice engrafted with MOLM13-LUC cells, the FLT3 inhibitor midostaurin and LIMKi delayed MOLM13-LUC engraftment as detected by in vivo bioluminescence imaging and the LIMKi and midostaurin combination prolonged significantly survival of leukemic mice. LIMK1/2 inhibition by the small molecule CEL_Amide seems to have promising activity in combination with FLT3 inhibitors in vitro as well as in vivo and may constitute a novel treatment strategy for FLT3-ITD+ AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
- Author
-
Massé, Aline, Roulin, Louise, Pasanisi, Justine, Penneroux, Justine, Gachet, Stéphanie, Delord, Marc, Ali, Ashfaq, Alberdi, Antonio, Berrou, Jeannig, Passet, Marie, Hernandez, Lucie, Quentin, Samuel, Gardin, Claude, Raffoux, Emmanuel, Adès, Lionel, Braun, Thorsten, Soulier, Jean, Clappier, Emmanuelle, Dombret, Hervé, and Puissant, Alexandre
- Subjects
- *
CELL physiology , *STEM cells , *LEUKEMIA , *GENE fusion , *GAMBLING - Abstract
Bromodomain and Extra-Terminal inhibitors (BETi) such as OTX015 are active in Acute Myeloid Leukaemias (AML). Their activity on Leukemic Stem Cells (LSCs) is less documented. We interrogated the anti-LSC activity of OTX015 in a niche-like long-term culture in 26 primary AML samples and validated our findings in vivo. OTX015 impaired LSCs in AMLs harbouring Core Binding Factor or KMT2A gene fusions, NPM1 or chromatin/spliceosome genes mutations, but not in those with aneuploidy/TP53 mutations. In four patients, we dissected the transcriptomic footprint of Bet inhibition on LSCs versus blasts. Our results can instruct future clinical trials of BETi in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.